JPWO2019157461A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019157461A5 JPWO2019157461A5 JP2020542604A JP2020542604A JPWO2019157461A5 JP WO2019157461 A5 JPWO2019157461 A5 JP WO2019157461A5 JP 2020542604 A JP2020542604 A JP 2020542604A JP 2020542604 A JP2020542604 A JP 2020542604A JP WO2019157461 A5 JPWO2019157461 A5 JP WO2019157461A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- encoded
- nucleic acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 32
- 150000007523 nucleic acids Chemical group 0.000 claims 32
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 230000011664 signaling Effects 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 230000009870 specific binding Effects 0.000 claims 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000013127 Vimentin Human genes 0.000 claims 4
- 108010065472 Vimentin Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 210000005048 vimentin Anatomy 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023223121A JP2024038225A (ja) | 2018-02-11 | 2023-12-28 | Ｃａｒ－ｔ細胞及び自己免疫疾患 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862629103P | 2018-02-11 | 2018-02-11 | |
| US62/629,103 | 2018-02-11 | ||
| PCT/US2019/017532 WO2019157461A1 (en) | 2018-02-11 | 2019-02-11 | Car-t cells and autoimmune diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023223121A Division JP2024038225A (ja) | 2018-02-11 | 2023-12-28 | Ｃａｒ－ｔ細胞及び自己免疫疾患 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021513337A JP2021513337A (ja) | 2021-05-27 |
| JPWO2019157461A5 true JPWO2019157461A5 (https=) | 2022-02-21 |
| JP2021513337A5 JP2021513337A5 (https=) | 2022-02-21 |
| JP7475686B2 JP7475686B2 (ja) | 2024-04-30 |
Family
ID=67549696
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542604A Active JP7475686B2 (ja) | 2018-02-11 | 2019-02-11 | Ｃａｒ－ｔ細胞及び自己免疫疾患 |
| JP2023223121A Withdrawn JP2024038225A (ja) | 2018-02-11 | 2023-12-28 | Ｃａｒ－ｔ細胞及び自己免疫疾患 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023223121A Withdrawn JP2024038225A (ja) | 2018-02-11 | 2023-12-28 | Ｃａｒ－ｔ細胞及び自己免疫疾患 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12421302B2 (https=) |
| EP (1) | EP3749778A4 (https=) |
| JP (2) | JP7475686B2 (https=) |
| KR (1) | KR102795055B1 (https=) |
| CN (2) | CN118878696A (https=) |
| AU (2) | AU2019216989B2 (https=) |
| BR (1) | BR112020016030A2 (https=) |
| CA (1) | CA3090891A1 (https=) |
| CL (1) | CL2020002066A1 (https=) |
| EA (1) | EA202091918A1 (https=) |
| IL (1) | IL276445A (https=) |
| MX (1) | MX2020008287A (https=) |
| SG (1) | SG11202007370RA (https=) |
| WO (1) | WO2019157461A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021219886B2 (en) | 2020-02-13 | 2025-01-23 | Imunopharm Technology Co., Ltd. | Optimization of chimeric antigen receptor |
| WO2021226589A1 (en) * | 2020-05-08 | 2021-11-11 | The University Of Kansas | Immunomagnetic compositions for the ph-specific capture of extracellular vesicles |
| US20230381228A1 (en) * | 2020-10-29 | 2023-11-30 | The Regents Of The University Of California | Anti-dpp6 chimeric antigen receptor bearing regulatory t cells |
| CA3226798A1 (en) * | 2021-07-29 | 2023-02-02 | James MATTHAEI | Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory t cells to treat autoimmune diseases |
| GB202202842D0 (en) * | 2022-03-01 | 2022-04-13 | Belgian Volition Srl | Chimeric antigen receptor T-cell treatments targeted to chromatin fragments and extracellular traps |
| CA3267341A1 (en) * | 2022-09-19 | 2024-03-28 | Sonoma Biotherapeutics, Inc. | Specific chimeric antigen receptors for a citrullinated antigen to target regulatory T lymphocytes for the treatment of hidradenitis suppurativa |
| WO2024254286A2 (en) * | 2023-06-07 | 2024-12-12 | Sonoma Biotherapeutics, Inc. | Methods of detecting citrullinated proteins |
| WO2025090985A1 (en) * | 2023-10-27 | 2025-05-01 | Duke University | Compositions comprising chimeric antigen receptors targeting citrullinated vimentin and methods of use thereof |
| WO2026008994A1 (en) | 2024-07-04 | 2026-01-08 | Quell Therapeutics Limited | Expression construct |
| WO2026020171A2 (en) * | 2024-07-19 | 2026-01-22 | Aera Therapeutics, Inc. | Chimeric antigen receptor constructs |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015010791A2 (en) * | 2013-07-24 | 2015-01-29 | Klareskog, Lars | Novel antibodies for the diagnosis and treatment of rheumatoid arthritis |
| AU2015209263A1 (en) * | 2014-01-24 | 2016-07-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-NY-BR-1 polypeptides, proteins, and chimeric antigen receptors |
| WO2016033331A1 (en) * | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| EP4074731A1 (en) * | 2015-11-04 | 2022-10-19 | City of Hope | Chimeric antigen receptors targeting her2 |
| WO2017100428A1 (en) * | 2015-12-09 | 2017-06-15 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
-
2019
- 2019-02-11 KR KR1020207025997A patent/KR102795055B1/ko active Active
- 2019-02-11 SG SG11202007370RA patent/SG11202007370RA/en unknown
- 2019-02-11 AU AU2019216989A patent/AU2019216989B2/en active Active
- 2019-02-11 WO PCT/US2019/017532 patent/WO2019157461A1/en not_active Ceased
- 2019-02-11 MX MX2020008287A patent/MX2020008287A/es unknown
- 2019-02-11 BR BR112020016030-0A patent/BR112020016030A2/pt unknown
- 2019-02-11 EP EP19751596.8A patent/EP3749778A4/en active Pending
- 2019-02-11 CN CN202410508213.9A patent/CN118878696A/zh active Pending
- 2019-02-11 US US16/968,794 patent/US12421302B2/en active Active
- 2019-02-11 EA EA202091918A patent/EA202091918A1/ru unknown
- 2019-02-11 JP JP2020542604A patent/JP7475686B2/ja active Active
- 2019-02-11 CN CN201980025160.2A patent/CN111954684B/zh active Active
- 2019-02-11 CA CA3090891A patent/CA3090891A1/en active Pending
-
2020
- 2020-08-02 IL IL276445A patent/IL276445A/en unknown
- 2020-08-10 CL CL2020002066A patent/CL2020002066A1/es unknown
-
2023
- 2023-12-28 JP JP2023223121A patent/JP2024038225A/ja not_active Withdrawn
-
2025
- 2025-11-26 AU AU2025271320A patent/AU2025271320A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513337A5 (https=) | ||
| US20220195388A1 (en) | Methods, kits and apparatus for expanding a population of cells | |
| JP2021532829A5 (https=) | ||
| Tassev et al. | Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor | |
| JP7604366B2 (ja) | 遺伝子操作されたｔ細胞を作製するための方法 | |
| JP2020108398A5 (https=) | ||
| JP2025023921A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| CN114174345B (zh) | 具有mage-a4特异性的嵌合抗原受体和其用途 | |
| Alonso-Camino et al. | CARbodies: human antibodies against cell surface tumor antigens selected from repertoires displayed on T cell chimeric antigen receptors | |
| JP2021511041A5 (https=) | ||
| JP2018516554A5 (https=) | ||
| Hanson et al. | ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models | |
| JP2012501669A5 (https=) | ||
| JPWO2019157461A5 (https=) | ||
| KR20190129062A (ko) | 항체 선택 방법 | |
| US20230181641A1 (en) | Process for producing donor-batched cells expressing a recombinant receptor | |
| JP2021514188A5 (https=) | ||
| JP2009278927A (ja) | Ｔ細胞受容体を模倣する抗体断片及びその製造方法 | |
| Wu et al. | Screening and identification of human ZnT8-specific single-chain variable fragment (scFv) from type 1 diabetes phage display library | |
| Perez et al. | Selective immunotargeting of diabetogenic CD 4 T cells by genetically redirected T cells | |
| WO2015087848A1 (ja) | タンパク質－磁性粒子複合体及びその製造方法 | |
| JPWO2019161133A5 (https=) | ||
| HK40073061A (en) | Methods, kits and apparatus for expanding a population of cells | |
| NZ762750B2 (en) | Anti-hla-a2 antibodies and methods of using the same | |
| RU2022101080A (ru) | Антитела к cd123, химерные антигенные рецепторы, связывающиеся с cd123, и т-клетки с химерными антигенными рецепторами, связывающимися с cd123 |